NIU Technologies Launches New Electric Scooter Series in Major U.S. Retailers

Published 23 hours agoNIU

NIU Technologies Launches New Electric Scooter Series in Major U.S. Retailers

NIU Technologies has unveiled its latest electric scooter lineup, the KQi 200 series, aiming to capture a larger share of the market. The series includes two models: the KQi 200P, retailing at $349 and available at Kohl's and Walmart, and the KQi 200F, priced at $449, available at Best Buy and online on platforms like Amazon and Shopify, as reported by GlobeNewswire.

This launch is significant as it marks NIU's first presence in Kohl's stores, expanding their reach into major U.S. retailers. The company strategically enhances its accessibility to customers by offering these new models both in-store and online. The introduction of the KQi 200 series is part of NIU's broader strategy to make electric mobility more widely available, particularly tapping into the mainstream retail market.

Both models offer features that cater to urban commuters. The KQi 200P is positioned as a high-performance yet affordable option, while the KQi 200F is designed with foldable handles, providing convenient portability. This move underscores NIU's commitment to providing innovative and practical mobility solutions to meet the demands of different consumer needs.

Share this article

Twitter Facebook LinkedIn

Recent Articles

UPS Plans Workforce Reduction and Facility Closures in Strategic Overhaul

UPS Plans Workforce Reduction and Facility Closures in Strategic Overhaul

1 minutes agoUPS

United Parcel Service (UPS) is set to undergo significant organizational changes as it prepares to cut 20,000 jobs and close 73 facilities by mid-2025. The logistics giant's decision is part of a broader strategy to streamline operations amid expectations of declining package volumes from its largest customer, Amazon. The Financial Times reports that UPS has reached an agreement with Amazon to reduce package delivery volumes by more than 50% by 2026. These strategic adjustments come in response to shifting market dynamics, with UPS aiming to pivot towards more profitable segments. The company announced a reported net income of $1.2 billion on $21.5 billion in first-quarter revenue for 2025, which was slightly below the analysts' expectations. However, its adjusted earnings per share of $1.49 surpassed the anticipated $1.38. UPS forecasts its 2025 revenue at $89 billion, below the analyst projections of $94.88 billion, primarily due to the planned reduction in Amazon shipments, as noted by Reuters. Additionally, UPS is focused on restructuring its U.S. domestic network by reducing its aircraft and vehicle fleets, generating $3.5 billion in cost savings for 2025. The restructuring efforts, while incurring $400–$600 million in expenses, reflect the company's commitment to optimizing profitability. Despite these initiatives, market reaction was mixed, with UPS shares dipping by 1% in pre-market trading following the announcements.

TriMas Aerospace Division Boosts Sales by 6.4%

TriMas Aerospace Division Boosts Sales by 6.4%

16 minutes agoTRS

TriMas Corporation's Aerospace division has recently reported a notable 6.4% increase in sales. This growth highlights the division's ability to meet high demand and indicates improvements in its operations, contributing positively to TriMas' overall stock performance. According to the latest numbers, the aerospace segment's impressive sales increase shows that operational enhancements have led to higher production yields and improved sales conversion rates. This advancement has played a significant role in investor confidence, as reflected in the company's improved stock performance. TriMas remains optimistic about the aerospace sector, anticipating continued strong demand. The company has emphasized that its strategy of focusing on operational excellence and market needs positions it well for ongoing success. As reported by Bloomberg, this focus is key to enhancing the overall performance of the company.

Pfizer Reports Q1 Revenue Shortfall, Cost-Cutting Boosts Earnings

Pfizer Reports Q1 Revenue Shortfall, Cost-Cutting Boosts Earnings

31 minutes agoPFE

Pfizer has released its first-quarter financial results for 2025, revealing a revenue of $13.72 billion, which missed analysts' expectations of $13.91 billion. This shortfall largely stems from a weaker-than-expected performance by its COVID-19 antiviral treatment, Paxlovid, which generated $491 million, below the anticipated $794.3 million. Despite this, adjusted earnings per share exceeded forecasts, reaching 92 cents compared to the expected 66 cents, according to Reuters. To address the revenue challenges, Pfizer has ramped up its cost-cutting efforts, targeting an additional $1.7 billion in savings through streamlined manufacturing and R&D operations, bringing total expected savings to $7.7 billion by 2027. The company has maintained its full-year revenue forecast of $58.5 billion to $61.5 billion, which comprises $5 billion from its COVID-19 vaccine and $3 billion from Paxlovid. Adjusted earnings per share for the year are expected to be between $2.15 and $2.35, as reported by NBC Los Angeles. Additionally, Pfizer is exploring the possibility of moving some of its overseas production to U.S. facilities in response to potential U.S. tariffs on pharmaceuticals. The company operates 10 manufacturing sites and two distribution centers in the U.S., employing nearly 10,000 workers. Despite the recent revenue miss, Pfizer's stock has only seen a slight 1% decrease in premarket trading, demonstrating resilience amid ongoing market adjustments.

Regeneron Shares Dip After Earnings Miss Due to Eylea Struggles

Regeneron Shares Dip After Earnings Miss Due to Eylea Struggles

46 minutes agoREGN

Regeneron Pharmaceuticals experienced a sharp downturn in its stock value following a disappointing earnings report. The company posted adjusted earnings of $8.22 per share, falling short of analysts' expectations of $8.82. Reuters highlighted that this was largely due to a decline in sales of Eylea, Regeneron's flagship eye drug, which saw a 26% drop in U.S. sales to $1.04 billion, below the anticipated $1.18 billion. This underperformance contributed to an overall revenue miss for the quarter, with the company reporting $3.03 billion against the expected $3.27 billion. The decline in Eylea sales is partly attributed to intensifying market pressures from more affordable alternatives and competition from Roche's Vabysmo. Additionally, Regeneron faced a regulatory setback when the FDA declined approval for a pre-filled syringe version of Eylea HD, due to issues with a third-party supplier. These challenges have weighed on the company's financial performance and led to a 7% drop in Regeneron's shares during premarket trading. Despite the hurdles with Eylea, Regeneron reported a 19% growth in sales of Dupixent, its leading anti-inflammatory medication, reaching $3.67 billion. However, this still fell short of forecasts. The company also faced disappointment with its cancer drug, Libtayo, which generated $285 million in sales, missing expectations of $340.5 million. Overall, these figures underscore the competitive and regulatory challenges Regeneron faces, even as it continues to drive growth in key segments.